Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder

Journal of Clinical Psychiatry

Volumn 77, Issue 3, 2016, Pages 371-378

  Durgam, Suresh ^a   Earley, Willie ^a   Guo, Hua ^a   Li, Dayong ^a   Németh, György ^b   Laszlovszky, István ^b   Fava, Maurizio ^c   Montgomery, Stuart A ^d  

^a FOREST RESEARCH INSTITUTE   (United States)

^b GEDEON RICHTER LTD   (Hungary)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIDEPRESSANT AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARIPRAZINE; CHOLESTEROL; CITALOPRAM; CREATINE KINASE; DULOXETINE; ESCITALOPRAM; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; PROLACTIN; SERTRALINE; TRIACYLGLYCEROL; VENLAFAXINE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; AKATHISIA; ARTICLE; BODY WEIGHT; CONSTIPATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV-TR; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEART RATE; HUMAN; INCREASED APPETITE; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SOMNOLENCE; SUICIDE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT; VITAL SIGN; XEROSTOMIA; ADOLESCENT; ADVERSE EFFECTS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; YOUNG ADULT;

EID: 84963624901     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10070     Document Type: Article

References (41)

1. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649-659. doi:10.16/S06-323(03)031-2 PubMed
2. Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007; 68 (suppl 8):17-25. PubMed
3. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry. 2000;61(suppl 2):10-12. PubMed
4. Han C, Wang SM, Kato M, et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother. 2013;13(7):851-870. doi:10.1586/143775.2013.8901 PubMed
5. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991. doi:10.176/pi.ajp.209.930312 PubMed
6. Wright BM, Eiland EH 3rd, Lorenz R. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy. 2013;33(3):344-359. doi:10.2/phar.1204 PubMed
7. Abilify (aripiprazole) [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc; 2014.
8. Seroquel XR (quetiapine fumarate extended-release) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2013.
9. Rexulti (brexapiprazole) [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc; 2015.
10. 2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328-340. doi:10.1124/jpet09.160432 PubMed
11. Kiss B, Horti F, Bobok A. Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr Res. 2012;136(suppl 1):S190. doi:10.16/S20-9964(12)7058-1
12. Slifstein M, Abi-Dargham A, D'Souza DC, et al. Cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: a clinical PET study with [11C]-(+)-PHNO. Neuropsychopharmacology. 2013;38(S2):S520.
13. Carnicella S, Drui G, Boulet S, et al. Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits. Transl Psychiatr. 2014; 4(6):e 401. doi:10.38/tp.2014.43 PubMed
14. Leggio GM, Salomone S, Bucolo C, et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol. 2013;719(1-3): 25-33. doi:10.016/j. ejphar.21307.02 Pub Med
15. Celada P, Puig M, Amargós-Bosch M, et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29 (4): 252-265. PubMed
16. Hayes R, Bose A, Lu K, et al. A double-blind, placebo-controlled study of cariprazine as adjunctive therapy in major depressive disorder. Presented at: the Autumn Conference of the International Society for CNS Clinical Trials and Methodology; October 3-4, 2011; Amelia Island, Florida.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
18. Oquendo MA, Baca-Garcia E, Kartachov A, et al. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry. 2003;64(7):825-833. doi:10.408/JCP.v64n0714 PubMed
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp13.4.382 PubMed
20. First MB, Williams JBW, Spitzer RL, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2007.
21. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168 (12):1266-1277. doi:10.1176/ai.ajp2.101704 PubMed
22. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95. doi:10.97/0004850-19603-00015 PubMed
23. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
24. Barnes TR. A rating scale for drug-induced ak athisi a. Br J Psychiatry. 1989;154 (5): 672-676. doi:10.192/bjp.145.672 PubMed
25. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:534-537.
26. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970; 212 (45):11-19. doi:10.11/j.160-0471970.tb206.x PubMed
27. Chen X, Luo X, Capizzi T. The application of enhanced parallel gatekeeping strategies. Stat Med. 2005;24(9):1385-1397. doi:10.2/sim.205PubMed
28. Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014;39(1):40-49. doi:10.1503/jpn.13040 PubMed
29. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540-549. doi:10.4088/JCP.08m04629 PubMed
30. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(7):917-932. doi:10.7/S14645710015 PubMed
31. Montgomery SA, Möller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 2009; 24 (3): 111-118. doi:10.1097/YIC.b01e283a8eb2PubMed
32. Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2010;127(1-3):19-30. doi:10.016/.jad.2108.032 PubMed
33. Jon DI, Kim H, Seo HJ, et al. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study. Clin Neuropharmacol. 2013;36(5):157-161. doi:10.97/WNF.0b0e3182a1f3d PubMed
34. Pae CU, Jeon HJ, Lee BC, et al. Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study. Int Clin Psychopharmacol. 2013; 28 (6): 322-329. doi:10.1097/YIC.b013e283643728 PubMed
35. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administrati on. PLoS Med. 2008;5(2):e45. doi:10.1371/journal.pmed.05045 PubMed
36. Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry. 2011;72(4):464-472. doi:10.4088/JCP.1m06191 PubMed
37. Melander H, Salmonson T, Abadie E, et al. A regulatory Apologia-A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol. 2008;18(9):623-627. doi:10.016/j.uroneuro.2086.03 PubMed
38. Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63-75. doi:10.1111/bdi.1238 PubMed
39. Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296-302. doi:10.16/jad.204.018 PubMed
40. Vlahiotis A, Devine ST, Eichholz J, et al. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans. J Manag Care Pharm. 2011;17(2):123-132. PubMed
41. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(suppl 6):16-22. PubMed